Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are…
By S. Branford, Z. Rudzki, Sonya Walsh, I. Parkinson, A. Grigg, J. Szer, K. Taylor, R. Herrmann, J. Seymour, C. Arthur and 3 more. Blood, 2003
777 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/f51e8e571d6b2ea33480686f3c15aa96be92389c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. O'hare
- Xin An
- A. Tiwari
- A. Bardelli
- C. Eide
- Yibo Sun
- P. Ding
- J. Tokarski
Citations in the corpus
- Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. (2007, background): “The enhanced transformation potency of several ATP binding loop mutants may also explain their association with poor prognosis in two retrospective studies.(25,33)”
- The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. (2006, background): “Importantly, all imatinib-resistant BCR-ABL mutations located in the phosphate-binding loop (P-loop) of ABL kinase, which have been associated with poor prognosis ( 17 ), were successfully targeted by dasatinib.”
- The biology of CML blast crisis. (2004, background): “newly diagnosed chronic-phase CML, and increases in frequency as time from diagnosis, or phase, progresses.(63,65) Last, point mutations can be found in blast crisis samples never exposed to tyrosine kinase inhibitors.”
- Liquid Biopsies: Genotyping Circulating Tumor DNA (2014, background): “Emergence of ABL kinase domain mutations have been extensively implicated in the pathogenesis of acquired resistance to imatinib.(73) Diaz and Bardelli”
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012, background): “11,36 Dasatinib and nilotinib are active against a number of imatinib-resistant mutants but are ineffective against subsets of mutants.”
- Chemotherapy and the war on cancer (2005, background): “, a finding usually associated with rapid emergence of resistanc”
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, background): “Mutations in the P-loop region are the most common, accounting for 36–48% of all mutations [94,97].”